Transcriptomic changes in oligodendrocytes and precursor cells associate with clinical outcomes of Parkinson’s disease

Table 1 Polygenic prediction of Parkinson’s measures in the Tuebingen patient sample

		UPDRS-III	Montreal cognitive assessment	Beck depression inventory-II
N		514	450	379
GBA1 model
GBA1_ODC_DEG	standardized beta	− 0.0297	0.002	− 0.060
	P value	0.549	0.959	0.299
GBA1_OPC_DEG	standardized beta	0.003	0.088	0.014
	P value	0.947	0.055^*	0.782
GBA1_MG_DEG	standardized beta	0.024	0.006	0.025
	P value	0.622	0.895	0.665
	Adj. R²	0.037	0.143	0.022
	Model P value	8.8 × 10^–4	4.4 × 10^–13	0.044
LRRK2 model
LRRK2_ODC_DEG	standardized beta	0.038	− 0.074	0.099
	P value	0.388	0.101	0.054^*
LRRK2_OPC_DEG	standardized beta	0.005	0.025	− 0.152
	P value	0.892	0.567	0.0002^**
LRRK2_MG_DEG	standardized beta	− 0.027	0.010	− 0.045
	P value	0.546	0.810	0.373
	Adj. R²	0.038	0.14	0.049
	Model P value	7.2 × 10^–4	8.1 × 10^–13	9.5 × 10^–4

The bold P-values are significant values i.e. P-value < 0.1
Linear regression using the sex, age and genetic principal components as control variables
^*Denotes significance at P ≤ 0.1
^**Denotes significance at P ≤ 0.05
UPDRS Unified Parkinson Disease Rating Scale, ODC Oligodendrocytes, OPC Oligodendrocytes precursor cells, MG Microglia, DEG Differentially expressed genes

ISSN: 1756-6606